Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Pasi Antero Janne, M.D.,Ph.D.

Co-Author

This page shows the publications co-authored by Pasi Janne and David M Jackman.
Connection Strength

2.492
  1. Jackman DM, Cioffredi L, Lindeman NI, Morse LK, Lucca J, Weckstein D, Huberman MS, Lynch TJ, Johnson BE, Janne PA. Phase II trial of erlotinib in chemotherapy-naive women with advanced pulmonary adenocarcinoma. J Clin Oncol. 2009 May 20; 27(15_suppl):8065.
    View in: PubMed
    Score: 0.463
  2. Jackman DM, Yeap BY, Lindeman NI, Fidias P, Rabin MS, Temel J, Skarin AT, Meyerson M, Holmes AJ, Borras AM, Freidlin B, Ostler PA, Lucca J, Lynch TJ, Johnson BE, Jänne PA. Phase II clinical trial of chemotherapy-naive patients > or = 70 years of age treated with erlotinib for advanced non-small-cell lung cancer. J Clin Oncol. 2007 Mar 01; 25(7):760-6.
    View in: PubMed
    Score: 0.394
  3. Jackman DM, Holmes AJ, Lindeman N, Wen PY, Kesari S, Borras AM, Bailey C, de Jong F, Jänne PA, Johnson BE. Response and resistance in a non-small-cell lung cancer patient with an epidermal growth factor receptor mutation and leptomeningeal metastases treated with high-dose gefitinib. J Clin Oncol. 2006 Sep 20; 24(27):4517-20.
    View in: PubMed
    Score: 0.385
  4. Jackman DM, Yeap BY, Sequist LV, Lindeman N, Holmes AJ, Joshi VA, Bell DW, Huberman MS, Halmos B, Rabin MS, Haber DA, Lynch TJ, Meyerson M, Johnson BE, Jänne PA. Exon 19 deletion mutations of epidermal growth factor receptor are associated with prolonged survival in non-small cell lung cancer patients treated with gefitinib or erlotinib. Clin Cancer Res. 2006 Jul 01; 12(13):3908-14.
    View in: PubMed
    Score: 0.379
  5. Jackman DM, Yeap B, Lucca J, Ostler PA, Morse LK, Fidias P, Lynch TJ, Temel J, Johnson BE, Janne PA. Phase II trial of erlotinib in elderly patients (age > 70) with previously untreated advanced non-small cell lung cancer (NSCLC): An analysis of quality of life and symptom response. J Clin Oncol. 2006 Jun 20; 24(18_suppl):7168.
    View in: PubMed
    Score: 0.378
  6. Jackman D, Lucca J, Fidias P, Rabin MS, Lynch TJ, Ostler P, Skarin AT, Temel J, Johnson BE, Janne PA. Phase II study of the EGFR tyrosine kinase erlotinib in patients = 70 years of age with previously untreated advanced non-small cell lung carcinoma. J Clin Oncol. 2005 Jun; 23(16_suppl):7148.
    View in: PubMed
    Score: 0.352
  7. Jackman DM, Sequist LV, Cioffredi L, Ruiz MG, Janne PA, Giaccone G, Miller VA, Johnson BE. Impact of EGFR and KRAS genotype on outcomes in a clinical trial registry of NSCLC patients initially treated with erlotinib or gefitinib. J Clin Oncol. 2008 May 20; 26(15_suppl):8035.
    View in: PubMed
    Score: 0.108
  8. Ortiz TM, Joshi VA, Heon S, Butaney M, Chen L, Jackman DM, Kwiatkowski DJ, Lindeman NI, Janne PA, Johnson BE. The introduction of systematic genomic testing for patients with non-small cell lung cancer (NSCLC) at Dana-Farber Cancer Institute (DFCI). J Clin Oncol. 2011 May 20; 29(15_suppl):7517.
    View in: PubMed
    Score: 0.033
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.